Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Have quite a few shares bought on impulse.....with profits from elseware. Are they good for medium to long term
Have invested before in this sort of share and have previously been moderately successful......what are the expert views on this one ,as now showing a substantial paper loss ,but I believe there has been a good announcement recently.......I am prepared to bee patient as not over exposed
http://tinyurl.com/ovzbd7y Darrin Disley, chief executive of Horizon Discovery Group (LON:HZD), discusses plans to scale-up the firm’s product inventory, put in place global sales channels and invest in the R&D side of the business. The CEO was speaking Proactive after releasing a after a positive set of half year results in which products revenue rose 73% to £3mln and services revenue jumped 205% to £5.4mln. AIM-listed Horizon has pioneered a way of editing genes with exceptional precision to produce what it calls ‘patients in a test tube’ or mutated cells. These can mimic thousands of permutations of diseases, against which new drugs can be tested by drugs companies, researchers and academics.
Hi Ronjoe. I believe it is just human typing error on this site, which is why I did my own research which I think is correct.
hi 4family my first post so be patient. The link to "Director's Talk" shows Panmure Gordon have set a target of 270 - article dated 16th September. I know this was their target on 20th July but on our site broker rating for 16th September is showing as 172. Hopefully i'm missing something here.
http://www.businessweekly.co.uk/news/biomedtech/california-deal-triggers-potential-horizon-gold-rush
Horizon Discovery Group PLC 55.2% Potential Upside Indicated by Panmure Gordon Posted by: Amilia Stone 16th September 2015 http://www.directorstalkinterviews.com/horizon-discovery-group-plc-55-2-potential-upside-indicated-by-panmure-gordon/412678473
Any ideas about the deal listed on another site about a large trade this morning for HZD? 2015-07-10 10:20:07 160.50 3,780,566 158.00 163.00 ? 6,067,808 O
I've dived into this interesting gene pool. Sold some of my Greenko yesterday by mistake as it was rocketing, so thought this is a good long term investment to spread risk.
Not often I find myself invested in a company before Neil Woodford spots it. Nice to have you on board mate.... GS
Horizon Discovery Group plc and Thermo Fisher Scientific Sign Supply and Commercialisation Agreement Horizon Discvry (LSE:HZD) Intraday Stock Chart Today : Monday 11 May 2015 Click Here for more Horizon Discvry Charts. Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, today announced it has signed a supply and commercialisation agreement with Thermo Fisher Scientific, the world leader in serving science. Under the terms of the agreement, Thermo Fisher will market and distribute Horizon’s X-MAN human haploid and diploid isogenic cell line collection and will further offer Horizon’s X-MAN haploid cell line generation service to its worldwide customer base with the exception of Japan. The exclusive distribution agreement for Japan between Horizon Discovery Group plc and Summit Pharmaceuticals International (SPI) remains unchanged. The X-MAN cell line range represents an extensive bank of genetically defined human cell lines – models that accurately exhibit disease-causing genetics, and have undergone a high degree of validation and quality control. These models help researchers to understand how complex genetic diseases manifest themselves, and can reduce the cost of bringing to market new personalized therapies by streamlining many aspects of drug development, including target identification, target validation, assay development, drug screening, lead optimization and biomarker-driven clinical trial design. The X-MAN catalogue includes both diploid (cells with two natural copies of each gene) cell lines and haploid (proprietary cells engineered to have only one copy of each gene) cell lines developed using Horizon’s proprietary precision (rAAV) and high-throughput (HT-CRISPR) genome-editing technologies. Additionally, Horizon offers rapid and low cost on-demand generation of engineered haploid cell lines that for the first time bring these valuable research tools to the 72,000+ research labs studying the basic and applied function of genes and genetic variation. All of Horizon’s X-MAN cell lines are provided as ‘isogenic pairs’, meaning that each modified cell is provided with a matched control so that when experiments are performed, researchers can attribute differences in experimental results with confidence to the specific genomic modification, which is difficult to do using historical patient-derived cell lines. Dr. Paul Morrill, President, Products, Horizon Discovery Group plc, commented: “This strategic agreement underscores the value of Horizon’s X-MAN cell line collection and gene editing services, and, in particular, highlights the impact Horizon’s haploid models are already having on the research community, following the acquisition of Haplogen Genomics GmbH in January 2015. Under this agreement, Thermo Fish
Dr. Paul Morrill, President, Products, Horizon Discovery Group, said: "To see our relationship with Transgenomic expand into a full OEM relationship after our initial collaboration project is a strong endorsement of Horizon's expertise in this field. We are dedicated to ensuring that cutting edge molecular diagnostic assays, such as those developed by Transgenomic, can demonstrate their true clinical significance and performance. We are delighted that they have chosen to make our reference material available with every MX-ICP kit purchase. This important relationship is part of our forward strategy to drive sustainable core revenue growth as well as take a scientific leadership role in the field of personalized medicine." "Incorporating Horizon's industry-leading controls into our MX-ICP kits supports our global commercialization campaign by providing customers and partners additional assurance of the exceptional performance of MX-ICP technology," said Paul Kinnon, Transgenomic's President and CEO. "The ultra-high sensitivity of MX-ICP enhances detection and identification of very low concentration, clinically important cancer mutations in tissue and liquid biopsies. Horizon's highly characterized and quantitative genomic DNA-based reference standards support the high performance of our MX-ICP technology. We expect that they will be especially valuable in clinical applications." cheers buzz
Morning all. We have just posted two short interviews (2mins each) we did with CEO Dr Darrin Disley. One is a general overview, the other based on today's results. You can watch both at the link below. I would welcome your feedback!! www.fmp-tv.co.uk/companies/horizon
but just a confirmation on expected improvements . A slight SP increase only is my guess we'll done long termers
CEO Darrin Disley will present at the Proactive Investor forum at the Chesterfield on 26th March. Click here to register: http://tinyurl.com/kmnj3yu
"Producing effective niche-busters is part of the new wave of personalised medicine and relies on identifying precisely why a patient has fallen ill and what it is about them that prevents them from responding to conventional drugs. Horizon Discovery helps drugs companies, researchers and academics do that." Mail on Sunday; March 15th, 2015; Medical firm that will broaden your Horizon Learn more about how Horizon Discovery is helping to make Personalized Medicine a reality at www.horizondiscovery.com, or read the full article at http://www.thisismoney.co.uk/money/investing/article-2994960/MIDAS-SHARE-TIPS-life-science-group-broaden-Horizon.html
Recd today by Midas share tips...should do well tomorrow.
All, HZN shares have risen well in the last few months. There have been some strong recommendations in the recent past, by various brokers/advisors/sites. What are peoples opinions, are the shares overpriced or are they still good value? Thanks
Good write up this month. Interesting to see if this is in their Portfolio 3 next month.... GLA GS
http://tinyurl.com/pgzkgdq Darrin Disley, the chief executive of Horizon Discovery (LON:HZD), says the strong share price performance could open the door to ‘further opportunities for acquisitions’. Disley discusses the company’s cash burn and being a ‘safe haven’ for investors’ money.
CEO Darrin Disley to update investors on 2nd October 2014 at the Chesterfield. Registrations: http://tinyurl.com/kzerl4z
wow this stock is rather unloved slow but constant drift down since day 1 , doesn't seem to be a standout reason or any reason! will sit and wait for news....